Vascularized Engineered Systems &
Synthetic Engineering Laboratory
Vascularized Engineered Systems &
Synthetic Engineering Laboratory
The VESSEL Lab develops advanced human organ-on-chip platforms with a primary focus on the liver. Our goal is to elucidate liver function in both health and disease. As an interdisciplinary and highly collaborative group, we integrate a multitude of bioengineering approaches – including synthetic biology, tissue fabrication, 3D printing, and microfluidic technologies – with expertise in vascular biology, stem cell biology, liver biology, genomics, and genetically engineered mouse models. Together, these approaches enable us to engineer physiologically relevant human 3D organotypic systems.
Fig 1: Vascularized liver on a chip
To accurately model the complex three-dimensional microenvironment of human organs, the VESSEL Lab places particular emphasis on engineering functional vascular systems, including both blood and lymphatic vessels, and incorporating them into 3D organotypic platforms. Through these vascularized human tissue models, we aim to uncover the biomolecular and biomechanical interactions between vascular networks and resident cells under both physiological and pathological conditions.
While these vascularized organotypic platforms are adaptable across multiple organs, our current focus is the liver due to its essential physiological roles and extraordinary regenerative capacity. The liver performs more than 500 critical functions to maintain whole-body homeostasis and is uniquely capable of restoring its mass following substantial injury. Despite these strengths, liver diseases continue to rise globally; for instance, metabolic dysfunction–associated steatotic liver disease (MASLD) now affects an estimated 38% of the global population.
Our research aims to model human liver physiology and to investigate how parenchymal cells, non-parenchymal cells, and the surrounding microenvironment act synergistically to maintain liver homeostasis or contribute to the progression of disease such as alcoholic fatty liver disease, MASLD, and cancer. In parallel, we are engineering vascularized liver tissues for potential therapeutic implantation as an alternative to liver transplantation.